• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

    9.570 -0.610 (-5.99%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,115,405
    Open 10.18
    Bid (Size) 9.610 (200)
    Ask (Size) 9.990 (100)
    Prev. Close 10.18
    Today's Range 9.550 - 10.59
    52wk Range 4.350 - 11.36
    Shares Outstanding 28,919,810
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    +75.9%
    +75.9%
    1 Month
    +4.6%
    +4.6%
    3 Month
    +32.5%
    +32.5%
    6 Month
    +61.7%
    +61.7%
    1 Year
    +45.7%
    +45.7%

    More News

    Read More
    News headline image
    Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data ↗
    Via MarketBeat
    News headline image
    Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at Upcoming Investor Conferences
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Pricing of Public Offering
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today ↗
    Via Stocktwits
    News headline image
    Candel Therapeutics Announces Proposed $100 Million Public Offering
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Candel Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Candel Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Candel Therapeutics, Inc. - Common Stock trade on?
    Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?
    The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market
    What is the current price of Candel Therapeutics, Inc. - Common Stock?
    The current price of Candel Therapeutics, Inc. - Common Stock is 9.570
    When was Candel Therapeutics, Inc. - Common Stock last traded?
    The last trade of Candel Therapeutics, Inc. - Common Stock was at 07/20/26 04:00 PM ET
    What is the market capitalization of Candel Therapeutics, Inc. - Common Stock?
    The market capitalization of Candel Therapeutics, Inc. - Common Stock is 276.76M
    How many shares of Candel Therapeutics, Inc. - Common Stock are outstanding?
    Candel Therapeutics, Inc. - Common Stock has 277M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.